| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec58c95352eaa96c1417aeb7844fad5e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-401 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-401
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-08 |
| filingDate |
2005-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2010-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d529b7dff35485577d37a6932b066850
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31d676eddaeb8e3a58f0a37a39a61669
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7eff2e4902452d620ae5bdfef55295f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9dee59fc73c83317c05c10d45d925a52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c67e9d32b62659f49c38128ca27b820c |
| publicationDate |
2010-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7691818-B2 |
| titleOfInvention |
Peptidomimetic inhibitors of retroviral proteases and their use as antivirals |
| abstract |
New peptidomimetic inhibitors of retroviral proteases are in particular for human immunodeficiency virus (HIV) protease. These inhibitors include as the core structure a new diamiriodiol isostere of the dipeptide Phe-Pro having four stereogenic centers. The inhibitors have been shown to inhibit HIV-protease and can therefore be usefully employed as antivirals for post-exposure prophylaxis and as a therapy for viral infections by a retrovirus, in particular HIV. The syntheses processes of the isosteres and inhibitors are also described. |
| priorityDate |
2004-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |